Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Investigators at University of Leeds zero in on breast cancer
May 8th, 2008
"Capecitabine added to docetaxel extends survival in metastatic breast cancer (MBC) and shows additive efficacy with erlotinib in pre-clinical studies. This study aimed to determine the maximum-tolerated dose (MTD) of capecitabine/docetaxel with erlotinib and assess tolerability, anti-tumour activity and potential pharmacokinetic interactions," scientists in Leeds, the United Kingdom report. "Three treatment cohorts were assessed, using different dosing regimens. A total of 24 women with MBC were enrolled sequentially. The regimen comprising erlotinib 100 mg/day continuously, capecitabine 825 mg/m(2) bid on days 1 to 14 and docetaxel 75 mg/m(2) intravenously every 3...
Source: Women's Health Weekly (2008-05-08)
|
